Tuesday, September 17, 2019

Management of Follicular Lymphoma (OncLive)

The website OncLive has another of its excellent video series. For these series, they ask a panel of experts to talk about the most recent developments in FL.

This series is called "Management of Follicular Lymphoma" and it features Dr. Ian Flinn from the Sarah Cannon Research Institute in Nashville, Dr. Matthew Lunning from the University of Nebraska Medical Center, Dr. John Pagel from the Swedish Cancer Institute in Seattle, Washington, and Dr. Pier Luigi Zinzani from the University of Bologna in Bologna, Italy. An excellent lineup.


The series is made up of 14 videos, each about 5 minutes long (give or take a minute or so). That's a lot of time, but it's worth it. They definitely get into the topic, and give a lot of good, up-to-date information about Follicular Lymphoma.


I'm not going to get into every one of the videos, but there are some highlights worth mentioning.


The opening video is called "Diagnosis of Follicular Lymphoma." As you can probably guess, it looks at what happens at diagnosis -- staging and grading and scanning. It gets into some of the choices that doctors and patients can make at that point.


The last video is called "Looking Ahead in Treating Follicular Lymphoma." And, of course, it gets into where FL treatment is going in the future.


And in between, the panel discusses issues such as maintenance, R-Squared, kinase inhibitors, and strategies for sequencing treatments.

As always, these kinds of "where we are" sites don't necessarily tell us something new. But they are helpful in putting all we know into one place, and giving us a chance to hear experts talk about some of the controversies that affect us.


And the lesson of it all -- even with some of the controversies -- is that we have lots to be hopeful about. There are lots of treatments out there, and more in the pipeline. And that's a great thing.


2 comments:

  1. There are lots of trials going on these days. The Archer-1 trial has delivered absolutely astonishing results (despite lov patient Count). Will be exiting to follow this study.

    LYMRIT 37-01 (relapsed iNHL) - median duration of response of 13.6 months for all responders and 32.0 months for complete responders

    Archer-1 - 100% ORR (3/3 complete response (CR)) in the first cohort of patients in a phase 1b study of Betalutin® + rituximab in relapsed/refractory follicular lymphoma


    ReplyDelete